

The Program could be subject to modification. Final program will be available during the congress and on the website

	Wednesday March 11th 2009	Wednesday March 11th 2009
	Pearl A	Crystal
14:00	<p>MANAGEMENT OF RISK FACTORS: FOCUS ON GUIDELINES ON THE LIGHT OF CLINICAL TRIALS Co-chair: F. Farhat (Lebanon) - P. Souaid (Lebanon)</p> <p>Antiplatelet therapy: Acute coronary syndrome and beyond How and how long JP Bassand (France)</p> <p>Guidelines on pre-diabetes and diabetes Fatemeh Rabiee (UK)</p> <p>Impact of the ENHANCE on our daily practice Leslie Cho (USA)</p> <p>Drugs affecting lipid metabolism: combination, interactions. A. Corsini (Italy)</p> <p>Thanks to an educational grant from Phenicia</p>	<p>DIDACTIC COURSE: What the General Cardiologist needs to know about catheter ablation Co-chair: B. Knight (USA) – L. Jordaens (the Netherlands)</p> <p>Normal and abnormal cardiac anatomy and its role in the genesis of arrhythmias M. Chauvin (France)</p> <p>Cardiac disease amenable to catheter ablation S. Nasr (Lebanon)</p> <p>Selection of optimal mapping and ablation techniques for specific arrhythmias and clinical circumstances J. Akar (USA)</p> <p>Identifying and minimizing the major risks associated with ablation G. Atallah (France)</p>
15:30	BREAK	BREAK
16:00	<p>DEBATED ISSUES ON MANAGEMENT OF RISK FACTORS Co-chair: B. Atallah (Lebanon) – N. Youakim (Lebanon)</p> <p>Dietary control and cardiovascular prevention R. Paoletti (Italy)</p> <p>Should everybody take aspirin in primary prevention? K. Khalifé (France)</p> <p>Exercise or sport: The good and the bad Fatemeh Rabiee (UK)</p> <p>CAD in women: the truth on hormonal replacement therapy Leslie Cho (USA)</p> <p>Thanks to an educational grant from Phenicia</p>	<p>ALL AROUND ABLATION OF ATRIAL FIBRILLATION Co-chair : A. Khadra (KSA) – L. De Roy (Belgium)</p> <p>Patient selection, patient preparation and patient Information J. Brachmann (Germany)</p> <p>New techniques, new energies, new mapping L. Jordaens (The Netherlands)</p> <p>Complications: How can we reduce the risk? E. Vester (Germany)</p> <p>How much monitoring to consider AF ablation a success? B. Knight (USA)</p> <p>Ablation of AF as first line therapy: too much ambition? N. Marrouche (USA)</p>
18:30	<p>Lecture chairman: C. Jazra (Lebanon) R. Ferrari (Italy)</p>	How much ACE inhibition has changed our daily practice
19:00	<p>Opening Ceremony Pearl A</p> <p>With the compliments of Servier</p>	

	Thursday 12 th March Pearl A	Thursday 12 th March Crystal Room	Thursday 12 th March Pearl C
09:00 A M	<p>CORONARY ARTERY DISEASE ARHHYTHMIA AND SUDDEN CARDIAC Co-chair: G. Ghanem (Lebanon) -</p> <p>How to manage an acute MI in 2009 JP Bassand (France)</p> <p>Management of chest pain at ER: Is CT scan of help? Martine Gilard (France)</p> <p>Cell transplantation for myocardial regeneration: Ready for prime time? R. Ferrari (Italy)</p> <p>Who needs an ICD after MI and when? Maria Teresa La Rovere (Italy)</p>		
10:30	BREAK	BREAK	BREAK
11:00 A M	<p>CLINICAL IMPLICATIONS OF REMODELING IN CVD Co-chair: W. Chalak (Lebanon) – JM Davy (France)</p> <p>Vascular remodeling and its consequences R. Asmar (France)</p> <p>Atrial remodeling and its role in atrial fibrillation TBA</p> <p>Ventricular remodeling and left ventricular dysfunction S. Alam (Lebanon)</p> <p>Therapeutic options: RAAS modulation and others R. Ferrari (Italy)</p> <p style="color: blue;">Thanks to an educational grant from Servier</p>	<p>MANAGEMENT OF SYNCOPE IN SPECIAL SITUATIONS Co-chair: M. Nohman (Qatar) – S. Abou Jaoudé (Lebanon)</p> <p>What is syncope and what is not? F. Bokhari (KSA)</p> <p>Algorithm for the diagnosis of syncope in patients without structural heart disease F. Abi Samra (USA)</p> <p>Algorithm for diagnosis of syncope in patients with structural heart disease B. Brembillat-Perrot (France)</p> <p>Algorithm for diagnosis and management of syncope in Athletes N. El Sherif (USA)</p>	<p>MECHANISM AND MANAGEMENT OF STROKE Co-chair: H. Abboud (Lebanon) -</p> <p>Insight in the mechanism of stroke: embolic-atherosclerotic H. Rupp (Germany)</p> <p>Is Holter monitoring mandatory in the management of Stroke? K. Kallab (Lebanon)</p> <p>Is there a consensus for the management of hypertension in the acute phase of stroke? A. Awada (Lebanon)</p> <p>Cerebrovascular protection after stroke: lessons from MOSES M. Grond (Germany)</p> <p style="color: blue;">Thanks to an educational grant from Solvay pharmaceuticals</p>
12:45	Mastering Lecture : Chairman: Prevention of Sudden death between Health and economics		G. Breithardt (Germany)
13:30 Luncheon Panel	<p>ARRHYTHMIAS AND SUDDEN DEATH IN PATIENTS WITH HEART FAILURE: Co-chair: A. AIMussaad (KSA) – J. Brachman (Germany)</p> <p>Mechanisms of arrhythmia in patients with LV dysfunction N. El-sherif (USA)</p> <p>Management of AF in heart failure patients A. Raviele (Italy)</p> <p>Management of ventricular tachyarrhythmia in Heart Failure G. Breithardt (Germany)</p> <p>Where ablation of AF in HF does stands? N. Marrouche (USA)</p>	<p>ABLATION OF ATRIAL FIBRILLATION: TECHNICAL AND CLINICAL ASPECTS Co-chair: A. Sayegh (Kuwait) – S. Choueiry (Lebanon)</p> <p>Is it time to send this patient for AF ablation? Usual and unusual indications W. Saliba (USA)</p> <p>AF Ablation: Why do we need different techniques? A. Katsivas (Greece)</p> <p>Early and late complications: detection and management. J. Kautzner (Czech Republic)</p> <p style="color: red;">Lunch is offered by St. Jude Medical</p>	<p>New approaches for the management of Diabetes Co-chair: A. Ehtay (Lebanon) – N. Bassil (Lebanon)</p> <p>The Case for Early Combination Therapy in the Management of Type 2 Diabetes B. Charbonnel (France)</p> <p>How to protect the kidney in the diabetic patient? A. barbari (Lebanon)</p> <p style="color: red;">Lunch is offered by MSD</p>
14:30			

	Thursday 12th March Pearl A	Thursday 12th March Crystal Room	Thursday 12th March Pearl C
P M	15 :00 Medtronic Symposium 16 :30	DEBATING THE GUIDELINES: WHICH ONE SHOULD WE FOLLOW? Co-chair: H. Mourad (Tunisia) – M. Fayyad (KSA) Atrial fibrillation N. Al Rawahi (Oman) CRT and ICD's JC Daubert (France) Syncope J. Mansourati (France) Ventricular tachycardia and sudden death G. Lascault (France)	THE WORKUP OF PATIENT WITH HYPERTENSION Co-chair: R. Tabalat (Jordan) – Z. Imad (Lebanon) Are we measuring the real blood pressure? H. Tamimi (Syria) Diagnostic and prognostic value of ambulatory measurement of blood pressure R. Asmar (France) Should we screen all hypertensive patients for Microalbuminuria? Therese Maroun (Lebanon) Cardiovascular imaging in hypertension E. Chammas (Lebanon) The challenge of systolic hypertension Y. Goussous (Jordan)
P M	BREAK	BREAK	BREAK
P M	17:00 CHALLENGES IN MANAGEMENT OF HEART FAILURE Co-chair: N. Timany (Lebanon) - W. Tarcha (Lebanon) Management of heart failure with preserved LV function H. Skouri (Lebanon) Management of heart failure in patients with renal failure M. Burnier (Switzerland) Anemia and and hyponatremia in Heart Failure S. Sayegh (Lebanon) Causes and management of non-responders to CRT G. Lascault (France) Management of sleep apnea in heart failure T. Kikano (Lebanon) 18:30 18:30	MANAGING THE ASYMPTOMATIC PATIENT WITH AN ABNORMAL ECG Co-chair: R. Mahmud (UAE) – E. Salamé (Lebanon) Long QT syndrome Kh. Daghri (KSA) Brugada Syndrome M. Borggreffe (Germany) Wolff-Parkinson-White Syndrome B. Brembillat-Perrot (France) Congenital AV block F. Bokhari (KSA)	COMBINATION THERAPY IN HYPERTENSION: RATIONALE AND RESULTS Co-chair: Evidence for the benefit of “ARB’s” in hypertension TBA Combining anti-hypertensive drugs: From Guidelines to practice R. Asmar (France) Thanks to an educational grant from NOVARTIS
		Symposium St. Jude Medical DIFFERENT TECHNIQUES FOR IMPLANTATION AND OPTIMIZATION OF CRT DEVICES Co-chair: A. Fagih (KSA) – M. Khoury (Lebanon) New techniques for CRT optimization: QuickOpt P. Mortensen (Denmark) CRT Implants: Techniques and Tricks A. Curnis (Italy)	Symposium Novartis Chairman: The RAAS: Where to block it, how to block it? M. Burnier (Switzerland)

	Friday 13 th March Pearl A	Friday 13 th March Crystal Room	Friday 13 th March Pearl C
09:00	ATRIAL FIBRILLATION FROM GENE TO BEDSIDE Co-chair: Y. Aoudia (Algeria) – J. Ziadé (Lebanon) Evaluation of patients with atrial fibrillation E. Vester (Germany) Where do the symptoms come from? JM Davy (France) Management of AF 2009: Lessons from echo, CT and MRI J. Maalouf (USA) Antithromboembolic treatment of atrial fibrillation: when, how and how long? J. Akar (USA) Can anticoagulation be stopped after AF ablation? Meleze Hocini (France)	Medtronic session	MAXIMIZING THE VASCULAR PROTECTION IN THE DYSGLYCEMIC PATIENT: AN EVIDENCE-BASED APPROACH Co-chair: S. Arnaout (Lebanon) - The benefit of glycemic control B. Charbonnel (France) Benefit of lipid lowering drugs: Statins, Fibrates or both? A. Corsini (Italy) Role of Glitazones S. Azar (Lebanon) ADVANCE's in the management of hypertension in the diabetic patient R. Asmar (France)
10:30	BREAK	BREAK	BREAK
11:00	CARDIAC RESYNCHRONIZATION: WHAT IS NOT IN THE GUIDELINES Co-chair: M. Chentir (Algeria) – A. Daou (Lebanon) Biventricular pacing in patients with bradycardia pacing indication Ph. Ritter (France) CRT in patients with atrial fibrillation J. Akar (USA) CRT indication in NYHA class II patients JC Daubert (France) CRT in patients with intermittent LBBB R. Mahmud (UAE)	DETECTION OF ARRHYTHMIAS AND RISK STRATIFICATION TOOLS Co-chair: H. Abdeddayem (Tunisia) – F. Abi Samra (USA) Evaluation of EF in the post MADIT and SCD-HEFT era. Variations and reproducibility W. Jaber (USA) How can heart rate variability and other parameters help in selecting patients for ICD Maria Teresa La Rovere (Italy) Indications and limitations of ambulatory electrocardiography N. El Sherif (USA) Role of implantable devices in the diagnosis of tachyarrhythmias L. Jordaens (The Netherlands)	Special Symposium of the MS institute (Middle East chapter) with a grant from Solvay Pharmaceuticals METABOLIC SYNDROME: AN EVOLVING CONCEPT Co-chair: R. Paoletti (Italy) – R. Nemr (Lebanon) The Metabolic Syndrome as a Risk Factor for Cardiovascular Disease G. Assmann (Germany) Prevalence of MS in Jordan A. Hammoudeh (Jordan) Prevalence of MS in Lebanon N. Houalla (Lebanon) Prevalence of MS in KSA Kh. Rubean (KSA) Drug Therapy for the Dyslipidemia of the Metabolic Syndrome JC Fruchart (France)
12:45	Mastering Lecture: Chairman: Do we need new guidelines for the management of dyslipidemia R. Paoletti (Italy)		
13:30	"Remote Home Monitoring: What's the Added Value?" Lunch is offered by Biotronik	INTERACTIVE SESSION: CASE PRESENTATION IN COLLABORATION WITH CADMOS Co-chair: J. Mansourati (France) – A. Kossaifi (Lebanon) 1. Atrial fibrillation J. Mansourati (France) 2. CRT P. Khattar (France) 3. ICD H. Mansour (France) 4. Tachyarrhythmia Cardiomyopathy in Child Y. Badaine (Jordan) 5. Tachyarrhythmia Cardiomyopathy in adult S. Nasr (Lebanon)	MANAGING THE RESIDUAL RISK FOR CVD Co-chair: JC Fruchart (France) - A review of Clinical trials on Statins and CVD R. Paoletti (Italy) Retinopathy as a risk factor for CVD TBA How to manage the non-responders to statins? TBA New data from FIELD study T. Keech (Australia) Lunch offered by Solvay Pharmaceuticals
15:00			

	Friday 13 th March Pearl A	Friday 13 th March Crystal Room	Friday 13 th March Pearl C
15:00 P M	<p>MAXIMIZING THE BENEFIT OF CARDIAC RESYNCHRONIZATION THERAPY Co-chair: A. Alheri (KSA) – M. Chauvin (France)</p> <p>What is the exact role of imaging in patient selection for CRT? W. Jaber (USA)</p> <p>Tics and Tricks in CRT lead implant failure A. Oto (Turkey)</p> <p>Are new technologies of help to improve the response Ph. Ritter (France)</p>	<p>CARDIOPACE™: WHEN DO WE NEED A SURGEON? In collaboration with the Lebanese Society of cardiothoracic surgery Co-chair: P. Karam (Lebanon) –</p> <p>Place of thoracoscopy in management of persistent atrial fibrillation L. de Roy (Belgium)</p> <p>CRT implantation failure: How can the surgeon be of help? R. Ashoush (Lebanon)</p> <p>Resynchronizing the heart after surgery for congenital HD R. Hneine (France)</p> <p>Surgical endoscopic resynchronization with robot Da Vinci F. Farhat (France)</p>	<p>DRUGS AFFECTING LIPID METABOLISM Co-chair:</p> <p>Lipoprotein particles and CAD: Lessons from COURAGE and ENHANCE Joe Maalouf (USA)</p> <p>HDL and atherosclerosis S. Jambart (Lebanon)</p> <p>The truth on HDL therapy R. Nemr (Lebanon)</p> <p>CRP as a risk factor or risk marker? W. Riesen (Switzerland)</p>
16:30	BREAK	BREAK	BREAK
17:00 P M	<p>SECOND DIDACTIC COURSE ON ICD IMPLANTATION AND FOLLOW-UP for the general cardiologist Co-chair: B. Kichou (Algeria) – N. Kadri (Jordan)</p> <p>Who needs an ICD in 2009? W. Saliba (USA)</p> <p>ICD implantation: techniques, DFT testing, and management of complications M. Khoury (Lebanon)</p> <p>ICD follow-up: troubleshooting, reprogramming, elective replacement indicators M. Chauvin (France)</p>	<p>WORKSHOP: MEET THE EXPERTS FROM PILL TO WIRE IN THE MANAGEMENT OF VENTRICULAR TACHYCARDIA Co-chair: H. Zouzou (Algeria) – S. Rafla (Egypt)</p> <p>How to diagnose a wide QRS tachycardia? N. Al Rawahi (Oman)</p> <p>Drug therapy to prevent VT JM Davy (France)</p> <p>Ablation of VT: Case reports L. De Roy (Belgium)</p> <p>ICD,s: unsolved issues F. Abi Samra (USA)</p>	<p>DIABETES IN HYPERTENSIVE PATIENTS: FROM ITS NEW-ONSET TO ITS COMPLICATIONS</p> <p>Abbott</p>
18:30	<p>How to manage arrhythmias in ICD recipients F. Abi Samra (USA)</p>		
18:30			<p>OBESITY AND THE CARDIOVASCULAR SYSTEM</p> <p>Abbott</p>

	Saturday 14 th March Pearl A	Saturday 14 th March Crystal room	Saturday 14 th March Pearl C
A M	<p>09:00</p> <p>DEBATES Co-chair: M. Borggreffe (Germany) – W. Haddad (Lebanon)</p> <p>Echo is mandatory in patient selection for CRT</p> <p>Pro W. Jaber (USA) Con J. Kautzner (Czech republic)</p> <p>All patients with EF <30% should receive an ICD</p> <p>Pro P. Milliez (France) Con F. Legal (France)</p> <p>10:30</p> <p>AAI is better than DDD in patients with sinus node dysfunction</p> <p>Pro M. Santini (Italy) Con Ph. Ritter (France)</p>	<p>ISSUES AND CONTROVERSIES IN CARDIAC PACING Co-chair: W. Khoury (Lebanon) -</p> <p>Are we pacing the “right” ventricle? D. Sayad (USA)</p> <p>Follow-up of children with pacemakers S. Al-Ghamdi (KSA)</p> <p>Percutaneous lead extraction: Techniques and complications W. Saliba (USA)</p> <p>Prophylactic antibiotherapy for cardiac pacing TBA</p> <p>Pacing for vaso-vagal syncope: Does it work? TBA</p>	<p>MYOCARDIAL INFARCTION AND HEART FAILURE AT THE CROSS-ROAD Co-chair:</p> <p>Diagnostic and prognostic value of BNP and pro-BNP R. Kassab (Lebanon)</p> <p>Evaluation of RV Function Joe Maalouf (USA)</p> <p>Role of Omega 3 fatty acids in the genesis of arrhythmia in MI and HF H. Rupp (Germany)</p> <p>Rethinking heart failure after GISSI-HF M. Khoury (UAE)</p> <p>Thanks to an educational grant from Solvay Pharmaceuticals</p>
	BREAK	BREAK	BREAK
A M	<p>11:00</p> <p>PREVENTION OF AF: AN EVIDENCE-BASED APPROACH Co-chair: Z. Smiri (Tunisia) –</p> <p>Antiarrhythmic agents for the prevention of paroxysmal and persistent AF H. Rizk (Egypt)</p> <p>Supportive therapy for AF: ACEI, ARB’S, Omega3, Magnesium M. Borggreffe (Germany)</p> <p>Statins to prevent AF Ch. Jazra (Lebanon)</p> <p>Can we prevent AF by pacing? M. Santini (Italy)</p> <p>Can Mitral valve repair prevent AF? V. Gebara (Lebanon)</p> <p>12:30</p>	<p>FROM PILL TO WIREAND DEVICES IN THE MANAGEMENT OF HEART FAILURE In collaboration with the Lebanese Society of cardiothoracic surgery Co-chair: Claude Semaan (Lebanon) - A. Dabbagh (Lebanon) -</p> <p>Debatable therapy (Digoxine, Spironolactone, dual RAAS inhibition...) H. Skouri (Lebanon)</p> <p>Electrical therapy: where are we, where are going to R. Sueidan(KSA)</p> <p>Cardiopulmonary assist F. Khalil (KSA)</p> <p>Benefit of revascularization M. Khoury (UAE)</p>	<p>WORKSHOP ON MANAGEMENT OF CV RISK FACTORS the International task force for prevention of CHD and the Lebanese society of atherosclerosis On invitation only by phenicia</p> <p>1. RISK FACTORS AND RISK MARKERS Co-chair:</p> <p>Risk stratification in atherosclerosis: Lessons from the PROCAM study G. Assmann (Germany)</p> <p>How can CT scan add to the risk stratification W. Jaber (USA)</p> <p>Old and new Markers for coronary artery disease R. Azar (Lebanon)</p> <p>Kidney disease as a cardiovascular risk factor A. Berbari (Lebanon)</p>
13:00 Luncheon Panel			<p>2. ATHEROSCLEROSIS: THERAPEUTIC CONSIDERATION Co-chair:</p> <p>Management of Dyslipidemia in the post-MI and Stroke W. Riesen (Switzerland)</p> <p>Targets in the management of diabetes I. Salti (Lebanon)</p> <p>Atherothrombosis: benefit of anti-platelet therapy K. Khalifé (France)</p> <p>Management of microalbuminuria: Evidence for Sulodexide A. Berbari (Lebanon)</p> <p>Lunch is offered by Phenicia</p>